1325 GMT - Novo Nordisk's deal with the U.S. government to lower weight-loss drug prices will hurt sales growth but gives it access to millions of additional patients, an aspect perhaps being overlooked by the markets, AlphaValue analyst Abhishek Raval writes. The agreement will see obesity drug prices comes down, mainly in return for a three-year tariff exemption and expanded Medicare/Medicaid access for obesity medicines, which might only have a negative low-single-digit impact on Novo Nordisk's 2026 sales growth. "Even though the sentiment around Novo's shares is extremely negative, we consider this to be the time for contrarians to enter the stock." The coming launch of a Wegovy pill could augur the turnaround of fortunes at Novo Nordisk, AlphaValue says. Shares rise 2.1%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 11, 2025 08:25 ET (13:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.